

1 Article

2

## 3 Serological Survey in a university community after the fourth 4 wave of COVID-19 in Senegal

5

6 Fatou THIAM <sup>1\*</sup>, Abou Abdallah Malick DIOUARA <sup>1</sup>, Clemence Stephanie Chloe Anoumba  
7 NDIAYE <sup>1</sup>, Ibrahima DIOUF <sup>2</sup>, Khadim KEBE <sup>1</sup>, Assane SENGHOR <sup>1</sup>, Djibaba DJOUMOI <sup>1</sup>,  
8 Mame Ndew MBAYE <sup>1</sup>, Idy DIOP <sup>3</sup>, Sarbanding SANE <sup>1</sup>, Seynabou COUNDOUL <sup>1</sup>, Sophie deli  
9 TENE <sup>1</sup>, Mamadou DIOP <sup>1</sup>, Abdou Lahat DIENG <sup>2</sup>, Mamadou NDIAYE <sup>4</sup>, Saidou Moustapha  
10 SALL <sup>2</sup>, Massamba DIOUF<sup>5</sup>, Cheikh Momar NGUER <sup>1</sup>

11 <sup>1</sup> Groupe de Recherche Biotechnologies Appliquées & Bioprocédés Environnementaux, École  
12 Supérieure Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-  
13 Fann, Senegal ; [fatou54.thiam@ucad.edu.sn](mailto:fatou54.thiam@ucad.edu.sn) (F.T.), [malick.diouara@ucad.edu.sn](mailto:malick.diouara@ucad.edu.sn) (A.A.M.D.),  
14 [anoumbachloe@gmail.com](mailto:anoumbachloe@gmail.com) (S.C.C.A.N.), [kebe.khadim@esp.sn](mailto:kebe.khadim@esp.sn) (K.B.), [azoozeng@hotmail.com](mailto:azoozeng@hotmail.com) (A.S.),  
15 [djibabadjoumoi@gmail.com](mailto:djibabadjoumoi@gmail.com) (D.D.), [mamendew.mbaye@esp.sn](mailto:mamendew.mbaye@esp.sn) (M.N.M.), [sarbandingsane@esp.sn](mailto:sarbandingsane@esp.sn)  
16 (S.S.), [seynaboucoundoul@esp.sn](mailto:seynaboucoundoul@esp.sn) (S.C.), [sophiedelitene@esp.sn](mailto:sophiedelitene@esp.sn) (S.D.T.), [mamadou.diop1@esp.sn](mailto:mamadou.diop1@esp.sn)  
17 (M.D.), [cmnguer@gmail.com](mailto:cmnguer@gmail.com) (C.M.N.)

18 <sup>2</sup> Laboratoire Physique de l'Atmosphère et de l'Océan-Siméon Fongang, École Supérieure  
19 Polytechnique, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Dakar  
20 10700 Senegal ; [ibrahima23.diouf@ucad.edu.sn](mailto:ibrahima23.diouf@ucad.edu.sn) (I.D.), [abdoulahat.dieng@ucad.edu.sn](mailto:abdoulahat.dieng@ucad.edu.sn) (A.L.D.),  
21 [saidou.sall@ucad.edu.sn](mailto:saidou.sall@ucad.edu.sn) (S.M.S)

22 <sup>3</sup> Laboratoire d'Imagerie Médicale et de Bio-Informatique, École Supérieure Polytechnique, Université  
23 Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal ; [idy.diop@esp.sn](mailto:idy.diop@esp.sn) (I.D.)

24 <sup>4</sup> Laboratoire Mathématiques Appliquées et Informatique, Faculté des Sciences et Techniques,  
25 Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085 Dakar-Fann, Senegal ;  
26 [mamadou1.ndiaye@unchk.edu.sn](mailto:mamadou1.ndiaye@unchk.edu.sn) (M.N.)

27 <sup>5</sup> Laboratoire Sante Publique, Institut d'odontologie et de Stomatologie, Faculte de Medecine, de  
28 Pharmacie et d'Odonthologie, Université Cheikh Anta Diop de Dakar, Corniche Ouest BP : 5085  
29 Dakar-Fann, Senegal ; [massamba.diouf@ucad.edu.sn](mailto:massamba.diouf@ucad.edu.sn) (M.D.).

30  
31 \* Correspondence: Email address: [fatou54.thiam@ucad.edu.sn](mailto:fatou54.thiam@ucad.edu.sn) (F.T.); Tel: +221786300621

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

47 **Abstract.**

48 Cross-sectional survey was conducted to assess the true extent of COVID-19 exposure  
49 among students and staff of Polytechnic High School (PHS). Random cluster sampling  
50 was carried out between May 19 and August 18, 2022, after the fourth wave of COVID-  
51 19 transmission. IgM and IgG SARS-CoV-2 antibodies were screened using WANTAI  
52 SARS-CoV-2 ELISA assays. Seroprevalence and descriptive statistics were calculated.  
53 Moreover, the associations between seropositivity and different factors (age, gender,  
54 preventive, etc.) were determined using logistic regression. A total of 637 participants  
55 were recruited, including 563 students, followed by 52 TAS officers, and 22 professors.  
56 The median age among was 21 years [18 - 63]. 62.0% of the participants were female,  
57 and 36.89% were male, with a male-to-female ratio = 0.59. The overall IgG and IgM  
58 seroprevalence were 92% and 6.91% respectively. We found a higher IgM  
59 seroprevalence in men than women (9.4% vs. 5.6%) and a lower IgM seroprevalence  
60 in (18-25) age group compared to (55-65) years. Low compliance with preventive  
61 measures was found with a significant IgM seroprevalence depending on non-respect  
62 of social distancing ( $p = 0.008$ ). IgM seropositivity was associated with Body Mass  
63 Indice (BMI) categorized (O.R. 0.238,  $p = 0.043$ ), ethnic group (O.R. 0.723,  $p = 0.046$ ) and  
64 marital status (O.R. 2.399,  $p = 0.021$ ). Moreover, IgG seropositivity was associated with  
65 vaccination status (O.R. 4.741,  $p < 0.001$ ). Our study revealed that the majority of  
66 students and staff have already been exposed to SARS-CoV-2, which confirms the  
67 circulation of SARS-CoV-2 in PHS at the time of the survey. Our results underline the  
68 importance of seroepidemiological surveys to estimate the real impact of the COVID-  
69 19 pandemic in a community and to monitor disparities in antibody response in the  
70 population.

71

72

73 **Keywords:** COVID-19; SARS-CoV-2 antibodies; sero-epidemiological survey;  
74 Polytechnic High School; Senegal.

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

## 91 **Introduction**

92 The Coronavirus 2019 (COVID-19), newly identified in December 2019 in Wuhan,  
93 China, is an infectious disease caused by Severe Acute Respiratory Syndrome  
94 Coronavirus 2 (SARS-CoV-2) [1, 2]. On January 30 2020, the World Health  
95 Organization (WHO) declared COVID-19 a public health emergency of global concern,  
96 and on March 11, 2020, it announced the COVID-19 epidemic as a pandemic [3]. By  
97 November 12, 2023, more than 697 million of people had been infected worldwide,  
98 with over 6.9 million deaths [4].

99 The COVID-19 outbreak had substantial economic, social, and health repercussions  
100 and damaging educational consequences [5-7]. In April 2020, the World Bank  
101 estimated that higher education institutions had been closed in 175 countries and that  
102 studies had been interrupted or significantly disrupted due to COVID-19, affecting  
103 more than 220 million students [8]. The pandemic forced academic communities to  
104 adopt online platforms for the continuity of teaching and learning activities, negatively  
105 impacting learning outcomes, particularly in developing countries where the lack of  
106 network infrastructures, computers, and internet access is challenging distance  
107 learning in developing countries [9, 10].

108 In Senegal, a West African country, the first case of SARS-CoV-2 was identified on  
109 March 2, 2020. Since then, the number of cases has risen considerably, and the country  
110 currently has more than 89,022 confirmed cases of COVID-19 and 1,971 deaths [11].  
111 The onset of the pandemic led the government authorities to close higher education  
112 establishments from March 16 to August 31 2020. The reopening of the establishments  
113 took place with the introduction of sanitary protocols that emphasized the  
114 reinforcement of barrier measures (wearing masks, hand washing with soapy water  
115 or hydroalcoholic gel, respect for social distancing and systematic taking of body  
116 temperature at campus access points) [12]. However, these measures have often been  
117 insufficient to stem the spread of the virus. Clusters quickly appeared in some  
118 establishments, including the Cheikh Anta Diop (CAD) University, located in Dakar,  
119 the capital of Senegal.

120 The failure of strategies to combat the spread of the virus could be linked to multiple  
121 factors, including (i) CAD University ecosystem, with its over 80,000 students from  
122 diverse origins. The consequence is overcrowding in student residences that caused  
123 the spread of the virus; (ii) the university environment is mainly populated by young  
124 people, who do not seem to be fully aware of the risks associated with the COVID-19  
125 health crisis [13]; (iii) the promiscuity in the Halls of residence, making it difficult to  
126 comply with social preventive measures; (iv) Lastly, lack of vaccine deployment and  
127 reluctance was noted among young people, which also contributes to low vaccination  
128 coverage in universities [14].

129 Faced with all these difficulties, it was essential to adopt cyclical measures to manage  
130 the COVID-19 pandemic, characterised by the virus spreading in waves [15, 16]. These  
131 measures could involve introducing survey studies based on diagnostic testing and  
132 mass screening protocols to diagnose and follow up with people exposed to or infected  
133 with SARS-CoV-2. In practice, detecting viral RNA by RT-PCR is the reference method  
134 for confirming the diagnosis of SARS-CoV-2 infection [17, 18]. However, access to

135 diagnostic tests still needs to be improved in poor countries [19]. The other way to  
136 estimate the true extent of the epidemic is to conduct Seroprevalence surveys [20, 21].  
137 Seroepidemiological studies to detect the presence of anti-SARS-CoV-2 antibodies are  
138 a valuable tool for assessing the timing of the epidemic. It can help to confirm the  
139 presence of a recent infection when PCR is limited. Some antibodies, such as IgG, can  
140 even be detected years after exposure [22]. Their detection can be used to identify  
141 previous or recent exposure to SARS-CoV-2. By carrying out this analysis on a  
142 representative population, it is possible to estimate what proportion of the population  
143 has already been exposed to the new coronavirus [23]. This information is helpful in  
144 identifying the epidemic phases and can help the authorities make decisions and even  
145 anticipate appropriate measures to contain the pandemic's spread [24]. Sero-  
146 epidemiological studies have been conducted in academic institutions such as  
147 universities in many countries [25-28]. However, more studies are highly relevant  
148 because university communities (faculty, staff and students) could be among the most  
149 exposed to SARS-CoV-2. In Senegal, no seroprevalence studies have been conducted  
150 in cohorts of educational institutions.

151 Therefore, we conducted an on-site screening project at Polytechnic High School (PHS),  
152 a public institution with an inter-African vocation at CAD University from May to  
153 August 2022 after the fourth wave of Coronavirus disease in Senegal. We aimed to  
154 assess the true extent of previous and recent COVID-19 exposition among students  
155 and staff and to investigate the risk factors associated with SARS-CoV-2 IgM and IgG  
156 seropositivity.

157

## 158 **2. Materials and Methods**

159

### 160 *2.1. Study Design and Population*

161 The SARSESP ("Etude de Seroprevalence du SARS-CoV-2 au sein de l'École Su-  
162 périeure Polytechnique", in the Cheikh anta DIOP University (CAD University))  
163 project is an on-site university population-based cross-sectional study. The sampling  
164 occurred at the PHS, an establishment of CAD University. Students, Professors, and  
165 Technicians, Administrative and Service (TAS) officers at SPS were invited by e-mail  
166 to enrol in the study. Participants were volunteers who registered online between 19  
167 May and 18 August 2022. A questionnaire was administered to each participant after  
168 consent, blood samples were taken for SARS-CoV-2 antibody detection.

169

### 170 *2.2. Sample Size Calculation*

171 We used stratified random sampling: the first stratum concerned professors, the  
172 second TAS officers and the third students. Systematic random sampling was used  
173 within each stratum to determine the required number of subjects. Using the lists  
174 provided by the student affairs and human resources departments, we calculated the  
175 sample size based on the hypothesis of an expected seroprevalence of 45%, with a  
176 precision of 5%, a design effect of 1.96, and a nonresponse rate of 65%. We determined  
177 that >450 participants needed to be recruited. To increase the accuracy of the results,  
178 this size was multiplied by 2, giving a sample size of 898, and rounded up to 1000 to

179 account for any lost records. The survey step for selecting statistical units was  
180 6133/1000, i.e. a step = 6. In this study, an allocation proportional to the size of each  
181 stratum was used. Thus, we considered a proportion of 83.54% for students, 9.97% for  
182 professors and 6.47% for TAS officers. Then, we obtained 65 TAS officers, 100  
183 professors and 835 students. The inclusion criteria were age over eighteen (18) years,  
184 informed consent signed, and questionnaire completion. Then, the non-inclusion  
185 criteria were under 18 years of age, non-consent and contraindications to venous blood  
186 sampling (anaemia, Infection or hematoma at a prospective venipuncture site, etc.).

187

### 188 *2.3. Questionnaire*

189 We shared an interviewer-administered questionnaire with participants on an  
190 electronic tablet (<https://enquete.ucad.sn/index.php/598685?lang=fr>). The  
191 questionnaire covered points regarding different factors to assess for relationships  
192 between IgM and IgG seropositivity and these factors. Questions relating to  
193 sociodemographic characteristics were collected, such as age, sex, occupation,  
194 education level, nationality, ethnic group and accommodation type. We also collected  
195 alcohol and tobacco intake, SARS-CoV-2 vaccination status, and preventive measures  
196 related to SARS-CoV-2 practices. We provided all recruitment participants with face  
197 masks and hand sanitisers and encouraged them to practice physical and social  
198 distancing. The questionnaire on COVID-19 was posted online by the IT and  
199 Information Systems Department of CAD University.

200

### 201 *2.4. Blood Collection and SARS-CoV-2 Antibodies Detection*

202 After each participant signed the written consent form, a 10 mL whole blood sample  
203 was collected into a dry vacutainer tube by standard venipuncture technique. Blood  
204 samples were centrifuged at 2,500 rpm for 10 minutes. Then, the plasma was collected  
205 and stored in cryotubes at -80°C at the GRBA-BE laboratory biobank in PHS until the  
206 tests were carried out. Seropositivity to anti-SARS-CoV-2 antibodies was used as a  
207 biomarker of exposure to the SARS-CoV-2 virus. IgM class immunoglobulins were  
208 used as a marker of recent or current infection (usually from days 5-7 after symptoms  
209 appear, but sometimes later and decrease at days 15-22), and IgG class  
210 immunoglobulins were used as a biomarker of older infection (detectable from day 11  
211 post symptom, reaching a maximum 3-4 weeks after and persist days 90 after) [29, 30].  
212 Serological tests were performed by qualitative ELISA for IgM and quantitative ELISA  
213 for IgG following the instructions for the WANTAI SARS-CoV-2 IgM ELISA (Beijing  
214 Wantai Biological Pharmacy Enterprise, Beijing, China; Ref. WS-1196 and WS-1396)  
215 recommended by the WHO for seroepidemiological studies, which detects total  
216 antibodies (including IgM and IgG) binding the SARS-CoV-2 spike protein receptor  
217 binding domain (S1/RBD) [31]. Serum samples were analysed in duplicate according  
218 to the supplier's recommendations.

219

### 220 *2.5. Statistical Analyses*

221 Statistical analyses were performed using Rstudio (version R 4.2.1) and GraphPad  
222 Prism (version 10.1.1 (316)) softwares. Continuous variables were described as mean

223 (standard deviation) or median (interquartile range). Normally distributed variables  
224 were compared with a t-test, and nonparametric data were compared with the Mann-  
225 Whitney test. Categorical variables were presented as percent, and Fisher exact tests  
226 or chi-squared tests were used for proportional assessments. For all statistical tests, we  
227 accepted a two-sided level of significance was set at  $p \leq 0.05$ .

228 SARS-CoV-2 seroprevalence was defined as the ratio of the number of people who  
229 developed anti-SARS-CoV-2 antibodies to the general population. Confidence  
230 intervals (95% CI) for seroprevalence were estimated using the Clopper-Pearson  
231 method. Using logistic regressions, we sought to understand how the IgM and IgG  
232 seropositivity are influenced by various variables such as age, gender, occupation,  
233 education level, nationality, type of accommodation, etc. The analyses were carried  
234 out after carefully handling the database and processing missing data.

235

### 236 *2.6. Ethics Statement*

237 This research complies with ethical recommendations. The project protocol has been  
238 validated by the National Health Research Ethics Committee (CNERS) of the Ministry  
239 of Health and Social Action. The research protocol was drawn up in accordance with  
240 Senegalese laws and regulations governing the confidentiality of personal data. The  
241 study was approved by the Senegalese National Ethics Committee for Research in  
242 Health (Reference number N°000043/MSAS/CNERS/SP, 28 February 2022).

243

## 244 **3. Results**

### 245 *3.1. Baseline characteristics of participants*

246 From the 1000 students, professors and TAS officers of PHS who were invited to  
247 participate in the study between 19 May 2022 and 18 August 2022, 637 (63.7%)  
248 participants were finally included (Figure 1). The most represented group was  
249 students (88.38%), followed by TAS officers (8.16%), and professors (3.45%). The mean  
250 age was 23.20 years, ranging from 18 to 63 years. The population's median age was 21  
251 years, with most participants aged 18 to 25 years, representing 85.7% of the population  
252 (Table I). 62.0% of the participants were female, and 36.89% were male, with a male-  
253 to-female ratio = 0.59. Most participants were Senegalese (94.66%) and lived in family  
254 homes (54.6%). In addition, most ethnic groups in the PHS population were Wolof  
255 (31.24%), Fula (24.33%) and Serer (21.98%). The prevalences of active smoking and  
256 taking alcohol were relatively low in the PHS community at the moment of the survey  
257 (1.9%) and (3.62%), respectively. Demographic data are shown in Table I. Calculation  
258 of body mass index also revealed the highest prevalence of normal weight (37.68%),  
259 followed by underweight (10.8%) and overweight/obesity, 8.32%. The most common  
260 blood group is O+ (47.08%). At the time of data collection, unvaccinated *vs.* vaccinated  
261 participants were 57.46% and 35.01 % respectively.

262

### 263 *3.2. Compliance with preventive measures and antibodies' seroprevalence*

264 Most respondents reported a low level of compliance with the following preventive  
265 measures recommended by the health authorities: 31.39% among participants declared  
266 that they had worn a mask always or often, and 18.21% observed a physical distance

267 (minimum 2 m) over the last 15 days. However, most participants reported a high level  
268 of compliance with hand washing: 75.35% had washed their hands always or often  
269 (Figure 2A). For social distancing, the majority of participants, 71.58%, reported 0-2  
270 frequencies of Participation in social events during the 15 days before the survey; 70.8%  
271 declared that they used public transport at least 2 times a day; and finally, 62.16% had  
272 visited someone 15 days before the survey (Figure 2B).

273

### 274 3.3. Seroprevalence of IgM et IgG SARS-CoV-2 antibodies

275 For overall participants, 6.91% (95% CI: 4.93 – 8.87) were seropositive for SARS-CoV-2  
276 IgM antibody, and 92% (95% CI: 89.90 – 94.11) were seropositive for SARS-CoV-2 IgG.  
277 Then, we analysed IgM and IgG seroprevalence according to the different  
278 characteristics of the study population shown in Table II.

279 Regarding IgM seroprevalence, the results showed significant age-dependence ( $p <$   
280  $0.001$ ) with higher seroprevalence in the (25-35) age group with 23.69% (95% CI: 20.39  
281 – 27) compared to (18-25) age group with 5.5% (95% CI: 3.73 – 7.27). According to  
282 gender, IgM seroprevalence was higher in men, 9.4% (95% CI: 7.13 – 11.67) than in  
283 women, 5.6% (95% CI: 3.51 – 7.38), but no significant differences were found by sex ( $p$   
284 = 0.83). There were no significant differences according to the other sociodemographic  
285 parameters regarding IgM antibodies seropositivity, such as occupation, level of  
286 education, ethnic group, accommodation type and size, but with some differences  
287 between sub-groups. For example, depending on the type of residence, we found a  
288 higher IgM seroprevalence among those living in halls of residence, 7.97% (95% CI:  
289 5.87 – 10.07) compared to those living in family homes, 6.68% (95% CI: 4.74 – 8.62)],  $p$   
290 = 0.73.

291 Concerning IgG seroprevalence, we found a significant difference between people  
292 who drank alcohol [95.24% (95% CI: 93.58 – 96.89)] and those who didn't [90.80%, (95%  
293 CI: 88.55, 93.04)], with  $p = 0.038$ . Then, a very significant difference was found  
294 according to vaccination status, with a high seropositivity rate in vaccinated people  
295 [96.83% (95% CI: 95.47 – 98.19)] compared to unvaccinated [86.58% (95% CI: 83.93 –  
296 89.22)],  $p < 0.0001$ . No significant difference was found between IgG seroprevalence  
297 according to age groups, while IgG seroprevalence was lower in men [89.9% (95% CI:  
298 87.60 – 92.24)] than in women [90.6% (95% CI: 88.33 – 92.87)],  $p = 0.98$ . Then, no  
299 significant differences were found by sex ( $p = 0.83$ ). IgM and IgG seroprevalences were  
300 higher in Professors and TAS officers than in students, yet this difference was not  
301 statistically significant ( $p = 0.71$ ).

302 Concerning antibodies' seroprevalence according preventive measures, we found a  
303 significant difference in IgM seroprevalence according to the 'number of visits made  
304 to someone' during the 15 days before the survey ( $p = 0.008$ ) (Table III). However, we  
305 found no significant difference in IgG seroprevalence and compliance with barrier  
306 measures.

307

### 308 3.5. Risk factors associated with SARS-CoV-2 IgM and IgG seropositivity among PHS 309 community

310 Multiple Logistic regression analysis didn't show an association between IgG  
311 seropositivity and the factors studied. Interestingly, an association between IgM  
312 seropositivity and participants' ethnic group [O.R. 0.723 95% CI: 0.49 – 0.96, ( $p = 0.046$ )]  
313 was reported (Table IV). Using a univariate analysis, we found a significant association  
314 between IgM seropositivity and marital status [O.R. 2.399 95% CI: 1.08 – 4.87 ( $p =$   
315  $0.021$ )], and Body Mass Indice (BMI) categorised [O.R. 2.015 95% CI: 1.12 – 3.56, ( $p =$   
316  $0.016$ )]. In addition, on one hand, we found a significant association between  
317 vaccination and IgG seropositivity [O.R. 4.741 95% CI: 2.25 – 11.65, ( $p < 0.001$ )]; on the  
318 other hand, no associations were observed between SARS-CoV-2 seropositivity and  
319 sex and age groups. Finally, no significant association were found between IgM and  
320 IgG seropositivity and preventive measures (Table V).

321  
322

#### 323 4. Discussion

324 This is the first sero-epidemiological survey of COVID-19 carried out in an educational  
325 establishment in Senegal. The study aimed to determine the seroprevalence of IgM  
326 and IgG SARS-CoV-2 antibodies and associated risk factors in order to assess the  
327 extent of virus exposure within the Polytechnic High School in Cheikh Anta Diop  
328 University. The survey was carried out on samples collected from personnel and  
329 students from May 2022 to August 2022, after the fourth wave of COVID-19 in Senegal.  
330 A total of 637 participants were included in the study, 62% of whom were women and  
331 37% men. The median age was 21, which is justified by the fact that the study was  
332 conducted in a university environment. Consequently, the study population  
333 predominantly comprises students representing around 86% of the participants.

334 We showed high IgG and IgM SARS-CoV-2 antibody seroprevalences of 92% (95% CI:  
335 89.90 – 94.11) and 6.91% (95% CI: 4.93 – 8.87), respectively. The IgM seroprevalence  
336 indicates that the virus was circulating within PHS at the time of the survey, with  
337 people who were currently or recently infected. Indeed, in seroprevalence surveys, it  
338 is recommended to use IgM and IgG detection to diagnose recent and previous  
339 infections [32]. IgM antibody levels rise around a week after the initial infection,  
340 indicating a recent infection [22]. IgG antibodies appear later than IgM antibodies  
341 (generally within 14 days of infection). They can persist for up to a year [33, 34],  
342 meaning that IgG antibodies serve as an indicator of an old infection [35].

343 The very IgG high seroprevalence could be due to increased exposure to the SARS-  
344 CoV-2 virus and the anti-COVID vaccination policy implemented by the authorities.  
345 Data from the Ministry of Health showed that our study occurred after the fourth wave  
346 of COVID-19 in Senegal in January 2022, and the deployment of the COVID-19 vaccine  
347 began in February 2021 [36], which could explain our result. The first seroprevalence  
348 surveys carried out in Senegal were conducted in 2020 after the first wave and showed  
349 a lower seroprevalence of around 20%. Between June and September 2020, Seck *et al.*  
350 found a SARS-CoV-2 seroprevalence rate of 21.1% (95% CI = 16.7–26.1%) [37]. During  
351 the same period, Ahoudi *et al.* conducted a study between June and October 2020.  
352 They found that the overall positivity rate was 20.4% and significant geographical  
353 differences in seropositivity with a higher seroprevalence in Dakar, around 40% [38].



354 Then, Talla *et al.* found an adjusted national prevalence of anti-SARS-CoV-2 IgG/IgM  
355 in Senegal estimated to be 28.4% between October 24 and November 26, 2020 [39]. A  
356 high SARS-CoV-2 seroprevalences and its variability between localities were also  
357 reported in the second national population based cross-sectional survey (72,2%)  
358 conducted in November 2021 [40] and among pregnant women attending the  
359 antenatal consultation (69,4%) during the second and third waves of COVID-19 in  
360 Senegal [41] .

361 Results showed a sharp increase in seroprevalence since 2020 in Senegal, and data  
362 corroborating the finding that several variants have circulated in the country,  
363 including the delta variant, which has been the most deadly and caused a peak in the  
364 number of confirmed cases in July 2021 [42]. Study carried out in Africa at the same  
365 time as our survey showed similarly high seroprevalence, with 74% between July and  
366 August 2022 in Bangui, Central African Republic [43]. In Nigeria, in early 2021, there  
367 was a high SARS-CoV-2 seroprevalence of 72.4% [44]. Given this situation, it seems  
368 very important to carry out cyclical epidemiological survey studies to measure the  
369 extent of the spread of the SARS-CoV-2.

370 Interestingly, we found a higher IgM seroprevalence in men than women (9.4% vs.  
371 5.6%). Then, our result would suggest that men are more sensitive to infection and/or  
372 reinfection with SARS-CoV-2 than women. A study conducted at the start of the  
373 pandemic by Takahashi *et al.* showed that men were more susceptible to severe forms  
374 of COVID-19 than women [45]. Gender differences in immune responses were also  
375 reported, with higher levels of pro-inflammatory cytokines (IL-8 and IL-18) and a  
376 more robust induction of non-classical monocytes in men [46]. This is consistent with  
377 studies that analysed the sex difference in antibody responses [47]. In further studies,  
378 it will be interesting compare immune responses according to gender and serological  
379 status in order to discover the mechanisms underlying sex differences.

380 Our results also showed a different distribution by age group, with lower IgM  
381 seroprevalence in younger individuals, particularly those aged 18-25 years, compared  
382 to those aged 55-65 years (5.5% and 33.34%, respectively) with a  $p < 0,001$ . The 18-25  
383 age group appears less affected by recent infections. This reinforces the data showing  
384 that young people are less affected by SARS-CoV-2 infection [48]. Furthermore, they  
385 often experience an asymptomatic or mild SARS-CoV-2 infection associated with  
386 lower serum titers [49]. In Senegal, during the first wave, it was reported that  
387 seroprevalence of SARS-CoV-2 was higher in patients older than 65 years [37].

388 We investigated whether there was a link between the type of residence and IgM  
389 seroprevalence to determine the proportion of new infections accordingly.  
390 Surprisingly, we didn't find a significant difference in terms of IgM seroprevalence  
391 among those living in halls of residence [7.97% (95% CI: 5.87 – 10.07)] compared to  
392 those living in family homes [6.68% (95% CI: 4.74 – 8.62)],  $p = 0.73$ . This invalidates our  
393 hypothesis that the particular ecosystem of CAD University, with its over 80,000  
394 students from diverse origins, would constitute a niche for spreading the virus, which  
395 is not proven in our study. It also appears that, even though the PHS community is  
396 mainly be composed by young people, they do not seem to facilitate new infection,  
397 contrary to what has been reported in other studies [48, 50].

398 Concerning compliance with preventive measures, we found a low level of compliance  
399 with preventive measures recommended by the health authorities, particularly for  
400 wearing masks (31.40%) and keeping a physical distance (minimum 2 m) (17.42%).  
401 However, most participants reported high-level compliance with hand washing  
402 (75.35%). Social distancing and staying at home were also registered although to a  
403 lower degree. Our results were in contradiction with those of Kearney *et al.* who  
404 observed high compliance with recommended COVID-19 prevention behaviors  
405 among their sample of Senegal respondents, particularly for masking and personal  
406 hygiene practices [51]. This difference could be explained by the fact that our study  
407 population is younger and less inclined to comply with preventive measures [52, 53].  
408 Our findings revealed that IgM seropositivity depends on the 'number of visits made  
409 to someone', meaning non-respect of social distancing ( $p = 0.008$ ), which shows the  
410 importance of WHO measures concerning the adoption of extensive social distancing  
411 as a non-pharmaceutical intervention to reduce the infection's spread and the  
412 associated mortalities [54]. However, studies have shown that the impact of social  
413 distancing measures depends upon a host of demographic, environmental, and  
414 economic dimensions [55].

415 Regarding vaccination, around 35% of participants had been partially or totally  
416 vaccinated, which is higher than the national vaccination rate of 16.9% at the moment  
417 of the survey [56]. This could be explained by our population's education level and  
418 knowledge of vaccination's stakes. Efforts were also made by the CAD University  
419 authorities, who set up a vaccination campaign at various sites during October 2021.  
420 However, the vaccination rate remains low compared to the national level, where more  
421 than 70% of the population vaccinated since the pandemic started [57].

422 Furthermore, we found no significant differences in IgM seroprevalences between  
423 vaccinated and unvaccinated individuals. It would, therefore, appear that vaccination  
424 does not protect against the new variants and reinfections, as has already been  
425 demonstrated in numerous studies [58-60] indeed, WHO recommendations suggest  
426 that seasonal vaccination is necessary to protect against new variants [61].

427 We investigated the association of sociodemographic, clinical and lifestyle factors,  
428 such as BMI, blood type, smoking and alcohol consumption, with seropositivity using  
429 logistics. Then, we found an association between BMI categorised and IgM  
430 seropositivity (O.R. 0.238,  $p = 0.043$ ). Previous studies have shown that obese  
431 individuals (BMI > 30 kg/m<sup>2</sup>) were significantly more likely to be seropositive. It is  
432 uncertain whether the raised seroprevalence in these groups represents a greater risk  
433 of SARS-CoV-2 infection. However, obese individuals are known to experience more  
434 severe COVID-19 symptoms [62, 63].

435 Interestingly, a significant association between IgM seropositivity and ethnic group  
436 was found (O.R. 0.723,  $p = 0.046$ ), suggesting a difference in susceptibility to SARS-  
437 CoV2- depending on race and ethnicity. According to previous findings, it seems there  
438 are disparities in the effects of COVID-19 infection among different racial/ethnic  
439 groups [64, 65]. Then, understanding the mechanisms for the disparity will help to  
440 evaluate the risk for COVID-19 according to ethnicity.

441 Our findings showed that IgM seropositivity was associated with marital status  
442 (unmarried/married) (O.R. 2.39,  $p = 0.021$ ); another study reveals that transmission of  
443 SARS-CoV-2 is variable among different people within the home. For instance, the risk  
444 for infection was higher between spouses, at 43%, which could be a reflection of  
445 transmission through intimacy or longer or more direct exposure [66].

446 Regarding vaccination status, we found a relationship between vaccination and IgG  
447 seroprevalence (O.R. 4.741,  $p < 0.001$ ), showing that people who had received vaccine  
448 doses were four times more likely to produce anti-SARS-CoV-2 antibodies than those  
449 who had not. It will be interesting to determine the IgG-neutralizing antibodies and to  
450 determine antibody levels according to vaccination status and type. Indeed, it has been  
451 shown that vaccines from different manufacturers might induce different antibody  
452 responses [67].

453

454 Some limitations of our study must be considered. By design, we carried out an on-  
455 site university population-based cross-sectional study. Thus, the results cannot be  
456 extrapolated directly to the general CAD University population. Participants were  
457 subjected to recall bias when completing the questionnaires, particularly preventive  
458 measures at the time of contact. We also noted a very low level of participation from  
459 professors and TAS officers. This constitutes a bias in the statistical calculations.  
460 Missing data for certain criteria and non-prefer responders were a limitation for  
461 statistics. To date, our study is the only SARS-CoV-2 sero-epidemiological survey  
462 conducted in a university community in Senegal. Data on the Serological testing  
463 performed by measuring IgM and IgG immunoglobulins against the SARS-CoV-2  
464 targeting peak S1 protein separately is a strength of our study. This allowed us to  
465 differentiate recent from previous infection. Finally, with our questionnaire we were  
466 able to collect a lot of data, which was useful in calculating associations with risk  
467 factors.

468

469 In summary, our analysis of more than 630 subjects from Polytechnic High School  
470 community members estimated the extent of exposure to SARS-CoV-2. Our study  
471 revealed a high seroprevalence from May–August 2022 following the fourth wave of  
472 COVID-19 in Senegal. Our results show that the majority of students and staff have  
473 already been exposed to SARS-CoV-2 and confirm the circulation of the virus (SARS-  
474 CoV-2) at the time of the survey as shown by the high IgM and IgG seroprevalence.  
475 The data show a link between seropositivity and various factors such as age, non-  
476 compliance with prevention measures. These results underline the importance of sero-  
477 epidemiological surveys to estimate the real impact of the COVID-19 pandemic and  
478 the disparities between populations in order to establish a profile of the transmission  
479 dynamics of the virus. In addition, these results may be essential for the CAD  
480 university in the event of the emergence of future waves in order to make appropriate  
481 decisions and put in place means of monitoring the evolution of the pandemic after  
482 the relaxation of social distancing measures and the implementation of a vaccination  
483 schedule at CAD University, which will serve as a basis for other universities in  
484 Senegal.

485 **Author Contributions:** “Conceptualization, F.T. and A.A.M.D, C.M.N, M.D.;  
486 methodology, F.T., A.A.M.D., C.S.C.A.N., S.S., S.D.T, S.C., A.S., D.D., and M.N.M;  
487 software, F.T., C.S.C.A.N., I.D., D.D., K.K., I.D.; A.L.D, M.D.; validation, F.T.,  
488 A.A.M.D., C.M.N., S.M.S.; formal analysis, F.T., K.K, C.S.C.A.N., I.D., D.D.; A.L.D.,  
489 M.D.; investigation, sample collection and biobank management, F.T., A.A.M.D.,  
490 M.N.M, C.S.C.A.N, D.D., S.C., S.S., S.D.T., A.S.; resources, F.T., A.A.M.D., S.M.S, M.D.;  
491 data curation, F.T., S.S., C.S.C.A.N., D.D.; writing—original draft preparation, F.T.;  
492 writing—review and editing, F.T., A.A.M.D., MNM, MD, CMN, KK, ID, SMS;  
493 visualization, F.T, A.A.M.D.; supervision, F.T.,A.A.M.D., S.M.S.,M.D.,C.M.N; project  
494 administration, F.T.; funding acquisition, F.T., A.A.M.D., and C.M.N. All authors have  
495 read and agreed to the published version of the manuscript

496  
497 **Funding:** This research was funded by Polytechnique High School competitive  
498 research impulse fund.

499  
500 **Institutional Review Board Statement:** The study was conducted in accordance with  
501 the Declaration of Helsinki, and approved approved by the Senegalese National  
502 Ethics Committee for Research in Health (Reference number  
503 N°000043/MSAS/CNERS/SP, 28 February 2022).

504  
505 **Informed Consent Statement:** Informed consent was obtained from all subjects  
506 involved in the study.

507  
508 **Data Availability Statement:** Not applicable.

509  
510 **Acknowledgments:** The authors would like to thank the top management of the  
511 “Ecole Supéri-eure Polytechnique de Dakar” for financial support and all students,  
512 Technicians, Administrative, Service officer and professors’ members who voluntarily  
513 participated to the study.

514  
515 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no  
516 role in the design of the study; in the collection, analyses, or interpretation of data; in  
517 the writing of the manuscript; or in the decision to publish the results”.

518  
519 **References**

- 520 1. Asselah T, Durantel D, Pasmant E, Lau G, Schinazi RF. COVID-19: Discovery, diagnostics and  
521 drug development. *J Hepatol.* 2021;74(1):168-84. Epub 20201008. doi: 10.1016/j.jhep.2020.09.031.  
522 PubMed PMID: 33038433; PubMed Central PMCID: PMC7543767.
- 523 2. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism,  
524 transmission, structural studies and therapeutics. *Infection.* 2021;49(2):199-213. Epub 20200904. doi:  
525 10.1007/s15010-020-01516-2. PubMed PMID: 32886331; PubMed Central PMCID: PMC7472674.
- 526 3. WHO Director-General’s opening remarks at the media briefing on COVID19 -March 2020.
- 527 4. <https://www.worldometers.info/coronavirus/> (accessed November 12, 2023).
- 528 5. Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al. Impact of COVID-19  
529 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic.

- 530 Sustain Prod Consum. 2021;26:343-59. Epub 20201014. doi: 10.1016/j.spc.2020.10.016. PubMed PMID:  
531 33072833; PubMed Central PMCID: PMCPMC7556229.
- 532 6. Hosseinzadeh P, Zareipour M, Baljani E, Moradali MR. Social Consequences of the COVID-19  
533 Pandemic. A Systematic Review. Invest Educ Enferm. 2022;40(1). doi: 10.17533/udea.iee.v40n1e10.  
534 PubMed PMID: 35485623; PubMed Central PMCID: PMCPMC9052715.
- 535 7. Shang Y, Li H, Zhang R. Effects of Pandemic Outbreak on Economies: Evidence From Business  
536 History Context. Front Public Health. 2021;9:632043. Epub 20210312. doi: 10.3389/fpubh.2021.632043.  
537 PubMed PMID: 33777885; PubMed Central PMCID: PMCPMC7994505.
- 538 8. World Bank Open Data. Data. <https://data.worldbank.org/> (2021).
- 539 9. Mok KH. Impact of COVID-19 on Higher Education: Critical Reflections. High Educ Policy.  
540 2022;35(3):563-7. Epub 20220811. doi: 10.1057/s41307-022-00285-x. PubMed PMID: 35971428; PubMed  
541 Central PMCID: PMCPMC9365678.
- 542 10. Selvaraj A, Radhin V, Ka N, Benson N, Mathew AJ. Effect of pandemic based online education  
543 on teaching and learning system. Int J Educ Dev. 2021;85:102444. Epub 20210608. doi:  
544 10.1016/j.ijedudev.2021.102444. PubMed PMID: 34518732; PubMed Central PMCID: PMCPMC8426326.
- 545 11. <https://www.worldometers.info/coronavirus/country/senegal/> (accessed  
546 November 12, 2023).
- 547 12. Diallo AI, Faye A, Tine JAD, Ba MF, Gaye I, Bonnet E, et al. Factors associated with the  
548 acceptability of government measures to address COVID-19 in Senegal. Rev Epidemiol Sante Publique.  
549 2022;70(3):109-16. Epub 20220331. doi: 10.1016/j.respe.2022.03.123. PubMed PMID: 35491335; PubMed  
550 Central PMCID: PMCPMC8968153.
- 551 13. Ba MF, Ridde V, Diallo AI, Tine JAD, Kane B, Gaye I, et al. Acceptability of contact management  
552 and care of simple cases of COVID-19 at home: a cross-sectional study in Senegal. Trans R Soc Trop Med  
553 Hyg. 2022;116(12):1214-22. doi: 10.1093/trstmh/trac094. PubMed PMID: 36222221; PubMed Central  
554 PMCID: PMCPMC9619604.
- 555 14. Nguyen KH, Nguyen K, Mansfield K, Allen JD, Corlin L. Child and adolescent COVID-19  
556 vaccination status and reasons for non-vaccination by parental vaccination status. Public Health.  
557 2022;209:82-9. Epub 20220613. doi: 10.1016/j.puhe.2022.06.002. PubMed PMID: 35870290; PubMed  
558 Central PMCID: PMCPMC9189141.
- 559 15. Zhou Y, Rahman MM, Khanam R. The impact of the government response on pandemic control  
560 in the long run-A dynamic empirical analysis based on COVID-19. PLoS One. 2022;17(5):e0267232. Epub  
561 20220504. doi: 10.1371/journal.pone.0267232. PubMed PMID: 35507588; PubMed Central PMCID:  
562 PMCPMC9067654.
- 563 16. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. Living with the  
564 COVID-19 pandemic: act now with the tools we have. Lancet. 2020;396(10259):1314-6. Epub 20201008.  
565 doi: 10.1016/S0140-6736(20)32117-6. PubMed PMID: 33038947; PubMed Central PMCID:  
566 PMCPMC7544497.
- 567 17. Torretta S, Zuccotti G, Cristofaro V, Etori J, Solimeno L, Battilocchi L, et al. Diagnosis of SARS-  
568 CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature. Ear Nose Throat J.  
569 2021;100(2\_suppl):131S-8S. Epub 20200831. doi: 10.1177/0145561320953231. PubMed PMID: 32865458;  
570 PubMed Central PMCID: PMCPMC7459180.
- 571 18. Chung YS, Lee NJ, Woo SH, Kim JM, Kim HM, Jo HJ, et al. Validation of real-time RT-PCR for  
572 detection of SARS-CoV-2 in the early stages of the COVID-19 outbreak in the Republic of Korea. Sci  
573 Rep. 2021;11(1):14817. Epub 20210720. doi: 10.1038/s41598-021-94196-3. PubMed PMID: 34285290;  
574 PubMed Central PMCID: PMCPMC8292370.
- 575 19. Maniruzzaman M, Islam MM, Ali MH, Mukerjee N, Maitra S, Kamal MA, et al. COVID-19  
576 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022;29(34):51384-97. Epub  
577 20220527. doi: 10.1007/s11356-022-21041-z. PubMed PMID: 35619009; PubMed Central PMCID:  
578 PMCPMC9135468.
- 579 20. Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2  
580 antibody: An up-to-date review. Int J Infect Dis. 2020;101:314-22. Epub 20201009. doi:  
581 10.1016/j.ijid.2020.10.011. PubMed PMID: 33045429; PubMed Central PMCID: PMCPMC7546669.


- 582 21. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S,  
583 et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. *Clin Microbiol*  
584 *Infect.* 2021;27(3):331-40. Epub 20201024. doi: 10.1016/j.cmi.2020.10.020. PubMed PMID: 33228974;  
585 PubMed Central PMCID: PMC7584920.
- 586 22. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in  
587 patients with coronavirus disease 2019. *Clin Transl Immunology.* 2020;9(5):e01136. Epub 20200506. doi:  
588 10.1002/cti2.1136. PubMed PMID: 32382418; PubMed Central PMCID: PMC7202656.
- 589 23. Feikin DR, Widdowson MA, Mulholland K. Estimating the Percentage of a Population Infected  
590 with SARS-CoV-2 Using the Number of Reported Deaths: A Policy Planning Tool. *Pathogens.* 2020;9(10).  
591 Epub 20201013. doi: 10.3390/pathogens9100838. PubMed PMID: 33066231; PubMed Central PMCID:  
592 PMC7602107.
- 593 24. Cascini F, Failla G, Gobbi C, Pallini E, Hui J, Luxi W, et al. A cross-country comparison of Covid-  
594 19 containment measures and their effects on the epidemic curves. *BMC Public Health.* 2022;22(1):1765.  
595 Epub 20220917. doi: 10.1186/s12889-022-14088-7. PubMed PMID: 36115936; PubMed Central PMCID:  
596 PMC9482299.
- 597 25. Vusirikala A, Whitaker H, Jones S, Tessier E, Borrow R, Linley E, et al. Seroprevalence of SARS-  
598 CoV-2 antibodies in university students: Cross-sectional study, December 2020, England. *J Infect.*  
599 2021;83(1):104-11. Epub 20210429. doi: 10.1016/j.jinf.2021.04.028. PubMed PMID: 33933527; PubMed  
600 Central PMCID: PMC8081745.
- 601 26. Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastitis E, et al.  
602 Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National  
603 and Kapodistrian University of Athens, Greece: A Preliminary Report. *Life (Basel).* 2020;10(9). Epub  
604 20200921. doi: 10.3390/life10090214. PubMed PMID: 32967110; PubMed Central PMCID:  
605 PMC7555935.
- 606 27. Arnold CRK, Srinivasan S, Rodriguez S, Rydzak N, Herzog CM, Gontu A, et al. SARS-CoV-2  
607 Seroprevalence in a University Community: A Longitudinal Study of the Impact of Student Return to  
608 Campus on Infection Risk Among Community Members. *medRxiv.* 2021. Epub 20210917. doi:  
609 10.1101/2021.02.17.21251942. PubMed PMID: 33619497; PubMed Central PMCID: PMC7899462.
- 610 28. Migliara G, Renzi E, Baccolini V, Cerri A, Donia P, Massimi A, et al. Predictors of SARS-CoV-2  
611 Infection in University Students: A Case-Control Study. *Int J Environ Res Public Health.* 2022;19(21).  
612 Epub 20221103. doi: 10.3390/ijerph192114376. PubMed PMID: 36361257; PubMed Central PMCID:  
613 PMC9655450.
- 614 29. Denning DW, Kilcoyne A, Ucer C. Non-infectious status indicated by detectable IgG antibody  
615 to SARS-CoV-2. *Br Dent J.* 2020;229(8):521-4. Epub 20201023. doi: 10.1038/s41415-020-2228-9. PubMed  
616 PMID: 33097885; PubMed Central PMCID: PMC7582419.
- 617 30. Assaid N, Arich S, Charoute H, Akarid K, Anouar Sadat M, Maaroufi A, et al. Kinetics of SARS-  
618 CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients. *Am J Trop Med*  
619 *Hyg.* 2023;108(1):145-54. Epub 20221212. doi: 10.4269/ajtmh.22-0448. PubMed PMID: 36509045; PubMed  
620 Central PMCID: PMC9833093.
- 621 31. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An  
622 evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. *Nat*  
623 *Commun.* 2020;11(1):3436. Epub 20200706. doi: 10.1038/s41467-020-17317-y. PubMed PMID: 32632160;  
624 PubMed Central PMCID: PMC7338506.
- 625 32. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al. Humoral  
626 response and PCR positivity in patients with COVID-19 in the New York City region, USA: an  
627 observational study. *Lancet Microbe.* 2020;1(7):e283-e9. Epub 20200925. doi: 10.1016/S2666-  
628 5247(20)30120-8. PubMed PMID: 33015652; PubMed Central PMCID: PMC7518831.
- 629 33. Ahmad A, Haq M, Rehman A, Haq NU. Anti-nucleocapsid IgG antibodies in SARS-CoV-2  
630 recovered health care workers: One year follow-up study. *Int J Immunopathol Pharmacol.*  
631 2023;37:3946320231187744. doi: 10.1177/03946320231187744. PubMed PMID: 37394899; PubMed Central  
632 PMCID: PMC10328170.
- 633 34. Haveri A, Ekstrom N, Solastie A, Virta C, Osterlund P, Isosaari E, et al. Persistence of  
634 neutralizing antibodies a year after SARS-CoV-2 infection in humans. *Eur J Immunol.* 2021;51(12):3202-

- 635 13. Epub 20211008. doi: 10.1002/eji.202149535. PubMed PMID: 34580856; PubMed Central PMCID:  
636 PMCPMC8646652.
- 637 35. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and  
638 IgG responses in COVID-19 patients. *Emerg Microbes Infect.* 2020;9(1):940-8. doi:  
639 10.1080/22221751.2020.1762515. PubMed PMID: 32357808; PubMed Central PMCID: PMCPMC7273175.
- 640 36. SMHSA (Senegalese Ministry of Health and Social Action)2022 [Final report of the 2nd  
641 seroprevalence survey of Covid-19 in Senegal, 2022.
- 642 37. Seck SM, Mbow M, Kane Y, Cisse MM, Faye G, Kama A, et al. Prevalence of SARS-CoV-2  
643 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study. *BMC Nephrol.*  
644 2021;22(1):384. Epub 20211117. doi: 10.1186/s12882-021-02582-w. PubMed PMID: 34789170; PubMed  
645 Central PMCID: PMCPMC8595275.
- 646 38. Ahoudi AD, Anderson M, Diedhiou CK, Dia A, Mbow M, Dia Y, et al. Seroprevalence of SARS-  
647 CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal. *IJID Reg.*  
648 2022;2:96-8. Epub 20211224. doi: 10.1016/j.ijregi.2021.12.008. PubMed PMID: 35721431; PubMed Central  
649 PMCID: PMCPMC8702669.
- 650 39. Talla C, Loucoubar C, Roka JL, Barry MA, Ndiaye S, Diarra M, et al. Seroprevalence of anti-  
651 SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between  
652 October and November 2020. *IJID Reg.* 2022;3:117-25. Epub 20220305. doi: 10.1016/j.ijregi.2022.02.007.  
653 PubMed PMID: 35720135; PubMed Central PMCID: PMCPMC8897837.
- 654 40. SMHSA (Senegalese Ministry of Health and Social Action)2023 [Final report of the 2nd  
655 seroprevalence survey of Covid-19 in Senegal, 2023.
- 656 41. Diouara, A. A., et al. High Exposure to SARS-CoV-2 among Pregnant Women after the First  
657 and Second Waves of COVID-19 in Senegal. Preprints. doi: 10.20944/preprints202310.1684.v1
- 658 42. Ndiaye AJS, Beye M, Lo G, Kacel I, Sow A, Leye N, et al. Genomic Epidemiology of SARS-CoV-2  
659 in Urban Settings in Senegal. *Viruses.* 2023;15(6). Epub 20230524. doi: 10.3390/v15061233. PubMed  
660 PMID: 37376533; PubMed Central PMCID: PMCPMC10302768.
- 661 43. Manirakiza A, Malaka C, Longo JD, Yambiyo BM, Diemer SH, Namsenei J, et al. Sero-  
662 prevalence of anti-SARS-CoV-2 antibodies among communities between July and August 2022 in  
663 Bangui, Central African Republic. *J Public Health Afr.* 2023;14(8):2315. Epub 20230605. doi:  
664 10.4081/jphia.2023.2315. PubMed PMID: 37753434; PubMed Central PMCID: PMCPMC10519115.
- 665 44. Akanmu S, Herrera BB, Chaplin B, Ogunola S, Osibogun A, Onawoga F, et al. High SARS-CoV-  
666 2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses. *J Clin Virol*  
667 *Plus.* 2023;3(3):100156. Epub 20230624. doi: 10.1016/j.jcvp.2023.100156. PubMed PMID: 37388808;  
668 PubMed Central PMCID: PMCPMC10289822.
- 669 45. Takahashi T, Wong P, Ellingson MK, Lucas C, Klein J, Israelow B, et al. Sex differences in  
670 immune responses to SARS-CoV-2 that underlie disease outcomes. *medRxiv.* 2020. Epub 20200626. doi:  
671 10.1101/2020.06.06.20123414. PubMed PMID: 32577695; PubMed Central PMCID: PMCPMC7302304.
- 672 46. Zhang H, Tang Y, Tao J. Sex-Related Overactivation of NLRP3 Inflammasome Increases  
673 Lethality of the Male COVID-19 Patients. *Front Mol Biosci.* 2021;8:671363. Epub 20210604. doi:  
674 10.3389/fmolb.2021.671363. PubMed PMID: 34150848; PubMed Central PMCID: PMCPMC8212049.
- 675 47. Zeng F, Dai C, Cai P, Wang J, Xu L, Li J, et al. A comparison study of SARS-CoV-2 IgG antibody  
676 between male and female COVID-19 patients: A possible reason underlying different outcome between  
677 sex. *J Med Virol.* 2020;92(10):2050-4. Epub 20200522. doi: 10.1002/jmv.25989. PubMed PMID: 32383183;  
678 PubMed Central PMCID: PMCPMC7267228.
- 679 48. Felsenstein S, Hedrich CM. SARS-CoV-2 infections in children and young people. *Clin Immunol.*  
680 2020;220:108588. Epub 20200906. doi: 10.1016/j.clim.2020.108588. PubMed PMID: 32905851; PubMed  
681 Central PMCID: PMCPMC7474910.
- 682 49. Backhaus I, Hermsen D, Timm J, Boege F, Lubke N, Degode T, et al. SARS-CoV-2 seroprevalence  
683 and determinants of infection in young adults: a population-based seroepidemiological study. *Public*  
684 *Health.* 2022;207:54-61. Epub 20220323. doi: 10.1016/j.puhe.2022.03.009. PubMed PMID: 35490440;  
685 PubMed Central PMCID: PMCPMC8940565.

- 686 50. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. *N Engl J*  
687 *Med.* 2020;382(17):1663-5. Epub 20200318. doi: 10.1056/NEJMc2005073. PubMed PMID: 32187458;  
688 PubMed Central PMCID: PMCPMC7121177.
- 689 51. Kearney M, Bornstein M, Fall M, Nianogo R, Glik D, Massey P. Cross-sectional study of COVID-  
690 19 knowledge, beliefs and prevention behaviours among adults in Senegal. *BMJ Open.*  
691 2022;12(5):e057914. Epub 20220526. doi: 10.1136/bmjopen-2021-057914. PubMed PMID: 35618332;  
692 PubMed Central PMCID: PMCPMC9136694.
- 693 52. Jaureguizar J, Redondo I, Galende N, Ozamiz N. Factors related to compliance with the COVID-  
694 19 health regulations among young people. *World J Psychiatry.* 2021;11(12):1247-58. Epub 20211219.  
695 doi: 10.5498/wjpv.v11.i12.1247. PubMed PMID: 35070774; PubMed Central PMCID: PMCPMC8717041.
- 696 53. Kim JK, Crimmins EM. How does age affect personal and social reactions to COVID-19: Results  
697 from the national Understanding America Study. *PLoS One.* 2020;15(11):e0241950. Epub 20201110. doi:  
698 10.1371/journal.pone.0241950. PubMed PMID: 33170903; PubMed Central PMCID: PMCPMC7654776.
- 699 54. Yoo TK, Oh E, Kim HK, Ryu IH, Lee IS, Kim JS, et al. Deep learning-based smart speaker to  
700 confirm surgical sites for cataract surgeries: A pilot study. *PLoS One.* 2020;15(4):e0231322. Epub  
701 20200409. doi: 10.1371/journal.pone.0231322. PubMed PMID: 32271836; PubMed Central PMCID:  
702 PMCPMC7144990.
- 703 55. Prakash N, Srivastava B, Singh S, Sharma S, Jain S. Effectiveness of social distancing  
704 interventions in containing COVID-19 incidence: International evidence using Kalman filter. *Econ Hum*  
705 *Biol.* 2022;44:101091. Epub 20211202. doi: 10.1016/j.ehb.2021.101091. PubMed PMID: 34894622; PubMed  
706 Central PMCID: PMCPMC8638209.
- 707 56. Singhal S, Prakash N. A narrative inquiry into the meaning of career identity of Indian emerging  
708 adults amid Covid-19. *Int J Educ Vocat Guid.* 2023:1-26. Epub 20230316. doi: 10.1007/s10775-023-09590-2.  
709 PubMed PMID: 37360271; PubMed Central PMCID: PMCPMC10019401.
- 710 57. Garg T, Votta CM, Prakash N, Deldin PJ. An investigation into the effectiveness of Mood Lifters  
711 in the context of trauma exposure. *Psychol Serv.* 2023. Epub 20230824. doi: 10.1037/ser0000789. PubMed  
712 PMID: 37616078.
- 713 58. Van Egeren D, Stoddard M, White LF, Hochberg NS, Rogers MS, Zetter B, et al. Vaccines Alone  
714 Cannot Slow the Evolution of SARS-CoV-2. *Vaccines (Basel).* 2023;11(4). Epub 20230416. doi:  
715 10.3390/vaccines11040853. PubMed PMID: 37112765; PubMed Central PMCID: PMCPMC10143044.
- 716 59. Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2  
717 mutations versus vaccine effectiveness: New opportunities to new challenges. *J Infect Public Health.*  
718 2022;15(2):228-40. Epub 20220105. doi: 10.1016/j.jiph.2021.12.014. PubMed PMID: 35042059; PubMed  
719 Central PMCID: PMCPMC8730674.
- 720 60. Lopez Bernal J, Gower C, Andrews N, Public Health England Delta Variant Vaccine  
721 Effectiveness Study G. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *Reply.*  
722 *N Engl J Med.* 2021;385(25):e92. Epub 20211110. doi: 10.1056/NEJMc2113090. PubMed PMID: 34758250.
- 723 61. Cohen JI, Burbelo PD. Reinfection With SARS-CoV-2: Implications for Vaccines. *Clin Infect Dis.*  
724 2021;73(11):e4223-e8. doi: 10.1093/cid/ciaa1866. PubMed PMID: 33338197; PubMed Central PMCID:  
725 PMCPMC7799323.
- 726 62. Wolff D, Nee S, Hickey NS, Marscholke M. Risk factors for Covid-19 severity and fatality: a  
727 structured literature review. *Infection.* 2021;49(1):15-28. Epub 20200828. doi: 10.1007/s15010-020-01509-  
728 1. PubMed PMID: 32860214; PubMed Central PMCID: PMCPMC7453858.
- 729 63. Aburto S, Cisterna M, Acuna J, Ruiz C, Viscardi S, Marquez JL, et al. Obesity as a Risk Factor  
730 for Severe COVID-19 in Hospitalized Patients: Epidemiology and Potential Mechanisms. *Healthcare*  
731 *(Basel).* 2022;10(10). Epub 20220922. doi: 10.3390/healthcare10101838. PubMed PMID: 36292285;  
732 PubMed Central PMCID: PMCPMC9601462.
- 733 64. Mackey K, Ayers CK, Kondo KK, Saha S, Advani SM, Young S, et al. Racial and Ethnic  
734 Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review. *Ann*  
735 *Intern Med.* 2021;174(3):362-73. Epub 20201201. doi: 10.7326/M20-6306. PubMed PMID: 33253040;  
736 PubMed Central PMCID: PMCPMC7772883.



- 737 65. Carethers JM. Insights into disparities observed with COVID-19. *J Intern Med.* 2021;289(4):463-  
738 73. Epub 20201206. doi: 10.1111/joim.13199. PubMed PMID: 33164230; PubMed Central PMCID:  
739 PMCPMC9325576.
- 740 66. Fogh K, Eriksen ARR, Hasselbalch RB, Kristensen ES, Bundgaard H, Nielsen SD, et al.  
741 Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark. *BMC Infect Dis.*  
742 2022;22(1):143. Epub 20220210. doi: 10.1186/s12879-022-07102-1. PubMed PMID: 35144550; PubMed  
743 Central PMCID: PMCPMC8830972.
- 744 67. Megasari NLA, Yamani LN, Juniastuti J, Lusida MI, Mori Y. Seroprevalence of SARS-CoV-2  
745 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java,  
746 Indonesia. *PeerJ.* 2023;11:e16142. Epub 20230925. doi: 10.7717/peerj.16142. PubMed PMID: 37780375;  
747 PubMed Central PMCID: PMCPMC10538276.
- 748



**Figure 1. Flowchart of participants' enrolment for the anti-SARS-CoV-2 antibody seroprevalence study in Superior Polytechnic School**

**Table I: Baseline characteristics of the study population**

Variable	Value, N (%)
<b>Overall</b>	637 (100)
<b>Age (years)</b>	
Mean	23.20
Median	21
Range	18 - 63
<b>Age group (years)</b>	
[18-25]	546 (85.71)
(25-35]	38 (5.96)
(35-45]	26 (4.08)
(45-55]	12 (1.88)
(55-65]	6 (0.94)
<b>Gender</b>	
Female	395 (62)
Male	235 (36.89)
<b>Occupation</b>	
Students	563 (88.38)
Professors	22 (3.45)
TASO	52 (8.16)
<b>Level of education</b>	
Bachelor degree	450 (70.64)
Master degree	117 (18.36)
PhD	20 (3.14)
others	18 (2.82)
<b>Nationality</b>	
Senegalese	603 (94.66)
Others †	32 (5.03)
<b>Ethnic groups</b>	
Wolof	153 (24.02)
Fula	139 (21.82)
Serer	79 (12.40)
Jola	16 (2.50)
Malinke	17 (2.67)
Soninke	9 (1.41)
Mauri	7 (1.1)
Others †	18 (2.82)
<b>Accommodation type</b>	
Halls of residence	138 (21.67)
Family home	479 (75.19)
<b>Family members</b>	
<b>Family members</b>	
1-2	37 (5.81)
3-5	247 (38.77)
6-8	188 (29.51)
9 or plus	74 (11.61)
<b>Matrimonial status</b>	
Single	558 (87.60)
Married	60 (9.42)
Divorced	2 (0.31)
<b>Smoker</b>	
Yes	10 (1.88)
No	538 (84.30)
Stopped > 1 year	10 (1.41)

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.29.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


<b>Alcohol consumer</b>	
Yes	21 (3.62)
No	554 (86.81)
Stopped > 1 year	3 (0.31)
<b>BMI Categorized</b>	
Underweight	69 (10.83)
Normal weight	240 (37.68)
Overweight /Obesity	53 (8.32)
<b>Blood Group</b>	
A-	9 (1.41)
A+	140 (21.98)
AB-	1 (0.15)
AB+	25 (3.92)
B-	5 (0.78)
B+	102 (16.01)
O-	24 (3.77)
<b>COVID-19 Vaccination</b>	
Yes	221 (35.01)
No	365 (57.46)
Prefer not to say	51 (7.54)

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

N number; BMI Body Mass Indice; TASO technicians, administrative and service officers

† For nationality and ethnic group, others correspond to others of African nationality or ethnic group with very small numbers (maximum 5)



**Figure 2:** Compliance with Preventive measures recommended by authorities

**Table II: Distribution of SARS-CoV-2 Ig M and G seropositive and seronegative individuals among the 637 participants enrolled.**

Variable	IgM			IgG		
	Seronegative N (%)	Seropositive N (%)	<i>p-value</i>	Seronegative N (%)	Seropositive N (%)	<i>p-value</i>
<b>Overall</b>	593 (93.09)	44 (6.91)		51 (8)	576 (92)	
<b>Age (years)</b>						
Mean	23.06	25.16		22.4	23.28	
Median	21	21		21	21	
Range	18 - 63	18 - 59		18 - 47	18 - 63	
<b>Age group</b>			<b>&lt;0,001*</b>			<b>0,98</b>
[18-25]	516 (94.50)	30 (5.5)		53 (9.7)	493 (92.3)	
(25-35]	29 (76.31)	9 (23.69)		4 (10.53)	34 (89.47)	
(35-45]	24 (92.31)	2 (7.69)		2 (7.69)	24 (92.31)	
(45-55]	12 (100)	0 (0)		1 (8.33)	11 (91.67)	
(55-65]	1 (66.67)	2 (99.99)		0 (0)	6 (100)	
<b>Gender</b>			<b>0.16</b>			<b>0.89</b>
Female	373 (94.43)	22 (5.57)		37 (9.36)	358 (90.63)	
Male	213 (90.64)	22 (9.36)		24 (10.21)	211 (89.79)	
<b>Occupation</b>			<b>0.15</b>			<b>0.71</b>
Students	528 (93.78)	35 (6.22)		55 (9.77)	508 (90.23)	
Professors	19 (86.36)	3 (13.64)		1 (9.61)	21 (90.38)	
TASO	46 (88.46)	6 (11.54)		5 (4.54)	47 (95.45)	
<b>Level of education</b>			<b>0.18</b>			<b>0.45</b>
Bachelor degree	423 (94)	27 (6)		46 (10.22)	404 (89.78)	
Master degree	105 (84.74)	12 (10.26)		12 (10.25)	105 (89.75)	
PhD	17 (85)	3 (15)		1 (5)	19 (95)	
others	16 (88.89)	2 (11.11)		0 (0)	18 (100)	
<b>Nationality</b>			<b>0.29</b>			<b>0.30</b>
Senegalese	565 (93.39)	40 (6.61)		56 (9.26)	549 (90.74)	
Others †	26 (86.67)	4 (13.33)		5 (16.67)	25 (83.33)	
<b>Ethnic groups</b>			<b>0.25</b>			<b>0.17</b>
Wolof	145 (94.77)	8 (5.23)		14 (9.15)	139 (90.85)	
Fula	128 (92.09)	11 (7.91)		11 (7.91)	128 (92.09)	
Serer	72 (91.14)	7 (8.86)		8 (10.13)	71 (89.87)	
Jola	14 (87.50)	2 (12.50)		0 (0)	16 (100)	
Malinke	16 (94.12)	1 (5.88)		3 (17.65)	14 (82.35)	
Soninke	9 (100)	0 (0)		3 (33.33)	6 (66.67)	
Mauri	7 (100)	0 (0)		0 (0)	7 (100)	
Others †	14 (77.78)	4 (22.22)		2 (11.12)	16 (88.88)	
<b>Accommodation type</b>			<b>0.73</b>			<b>0.76</b>
Halls of residence	127 (92.03)	11 (7.97)		12 (8.69)	126 (91.31)	
Family home	447 (93.32)	32 (6.68)		48 (10.02)	431 (89.98)	
<b>Family members</b>			<b>0.54</b>			<b>0.32</b>
1-2	36 (97.30)	1 (2.70)		2 (5.40)	35 (94.60)	
3-5	227 (91.90)	20 (8.10)		29 (11.75)	218 (88.25)	
6-8	176 (93.62)	12 (6.38)		20 (10.64)	168 (89.36)	
9 or plus	78 (90.70)	8 (9.30)		5 (5.81)	81 (94.19)	
<b>Matrimonial Status</b>			<b>0.062</b>			<b>0.53</b>
Single	524 (93.9)	34 (6.1)		54 (9.68)	504 (90.32)	
Married	51 (85)	9 (15)		7 (11.67)	53 (88.33)	
Divorced	2 (100)	0 (0)		0 (0)	2 (100)	
<b>Smoker</b>			<b>0.08</b>			<b>0.16</b>
Yes	10 (100)	0 (0)		0 (0)	14 (100)	
No	503 (93.49)	35 (6.51)		57 (9.69)	531 (90.31)	
Stopped > 1 year	8 (80)	2 (20)		0 (0)	10 (100)	
<b>Alcohol consumer</b>			<b>0.12</b>			<b>0.038</b>
Yes	19 (90.48)	2 (9.52)		1 (4.76)	20 (95.24)	

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

No	516 (93.14)	38 (6.86)		51 (9.20)	503 (90.80)	
Stopped > 1 year	3 (100)	0 (0)		1 (33.34)	2 (66.66)	
<b>BMI Categorized</b>			0.089			0.55
Underweight	67 (97.10)	2 (2.90)		6 (8.70)	63 (91.30)	
Normal weight	224 (93.33)	16 (6.67)		28 (11.67)	212 (88.33)	
Overweight /Obesity	46 (86.79)	7 (11.36)		8 (15.09)	45 (84.91)	
<b>Blood Group</b>			0.95			0.094
A-	8 (88.89)	1 (11.11)		1 (11.11)	8 (88.89)	
A+	131 (93.57)	9 (6.43)		14 (10)	126 (90)	
AB-	1 (100)	0 (0)		1 (100)	0 (0)	
AB+	24 (96)	1 (4)		3 (12)	22 (88)	
B-	4 (80)	1 (20)		0 (0)	5 (100)	
B+	94 (92.16)	8 (7.84)		7 (6.86)	95 (93.14)	
O-	22 (91.67)	2 (8.33)		1 (4.17)	23 (95.83)	
O+	279 (93)	21 (7)		29 (9.67)	271 (90.33)	
<b>COVID-19 Vaccination</b>			0.624			<0.0001
Yes	203 (91.85)	18 (8.15)		7 (3.17)	214 (96.83)	
No	340 (95.15)	25 (6.85)		49 (13.42)	316 (86.58)	
Prefer not to say	50 (98.04)	1 (1.96)		5 (9.8)	46 (90.2)	

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

\*Statistics were calculated without missing values. Missing values were excluded from the analysis

**Table III.** Distribution of Sars-Cov-2 Ig M and G seropositive and seronegative according to preventive measures

	IgM			IgG		
	Seronegative n (%)	Seropositive n (%)	<i>p</i> - <i>value</i>	Seronegative n (%)	Seropositive n (%)	<i>p</i> - <i>value</i>
<b>Wearing masks</b>			<b>0.17</b>			<b>0.73</b>
Always/Often	183 (91.04)	18 (8.96)		19 (9.45)	182 (90.55)	
Sometimes/Rarely	355 (93.42)	25 (6.58)		38 (10)	342 (90)	
Never	30 (100)	0 (0)		4 (13.33)	26 (86.67)	
<b>Kept a physical distance of 2 m</b>			<b>0.35</b>			<b>0.33</b>
Always/Often	110 (94.83)	6 (5.17)		8 (6.90)	108 (93.10)	
Sometimes/Rarely	277 (91.42)	26 (8.58)		31 (10.23)	272 (89.77)	
Never	161 (94.15)	10 (5.85)		21 (12.28)	150 (87.72)	
<b>Wash hands with hydroalcoholic or with soap and water</b>			<b>0.105</b>			<b>0.599</b>
Always/Often	451 (93.96)	29 (6.04)		51 (10.62)	429 (89.38)	
Sometimes/Rarely	108 (88.52)	14 (11.48)		10 (8.20)	112 (91.80)	
Never	4 (100)	0 (0)		0 (0)	4 (100)	
<b>Number of visits received in the last 15 days</b>			<b>0.583</b>			<b>0.971</b>
0-2	205 (93.61)	14 (6.39)		23 (10.50)	196 (89.50)	
3-8	188 (92.16)	16 (7.84)		21 (10.29)	183 (89.71)	
≥9	146 (94.80)	8 (5.20)		15 (9.74)	139 (90.26)	
<b>Number of visits made in the last 15 days</b>			<b>0.008*</b>			<b>0.946</b>
0-2	373 (94.20)	23 (5.81)		41 (10.35)	355 (89.65)	
3-8	109 (87.20)	16 (12.80)		12 (9.60)	113 (90.40)	
≥9	73 (97.33)	2 (2.67)		7 (9.33)	68 (90.67)	
<b>Public transport use per day over the last 15 days</b>			<b>0.878</b>			<b>0.668</b>
0-2	419 (92.9)	32 (7.1)		44 (9.75)	407 (90.25)	
3-5	105 (92.92)	8 (7.1)		14 (12.39)	99 (87.61)	
≥9	33 (91.67)	3 (8.33)		3 (8.33)	33 (91.67)	
<b>Participation in a social event in the last 15 days</b>			<b>0.589</b>			<b>0.289</b>
0-2	423 (92.76)	33 (7.24)		51 (11.18)	405 (88.82)	
3-8	79 (90.80)	8 (9.20)		5 (5.75)	82 (94.25)	
≥9	44 (95.65)	2 (4.35)		4 (8.70)	42 (91.30)	

Significant values are in bold.

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Table IV: Multiple logistic regression of sociodemographical risk factors affecting seropositivity**

Variable	IgM				IgG			
	Univariate OR (95% CI)	<i>p</i> -value	Multivariate OR (95% CI)	<i>p</i> -value	Univariate OR (95% CI)	<i>p</i> -value	Multivariate OR (95% CI)	<i>p</i> -value
Age	1.034 [0.99 - 1.06]	0.055	0.971 [0,74 -1,21]	0,808	1.023 [0.98 - 1.081]	0.345	0.974 [0.89 - 1.071]	0.573
Gender	1.75 [0.943 - 3.25]	0.073	0.776 [0,10 - 4.6]	0.791	0.906 [0.53 - 1.578]	0.728	0.913 [0.52 - 1.62]	0.757
Occupation	1.652 [0.92 - 2.72]	0.065	1.345[0,06 - 22.03]	0.834	1.26 [0.69 - 2.75]	0.508	2.545 [0.60 - 15.33]	0.250
Level of education	1.526 [0.91 - 2.47]	0.095	1.709 [0.31 - 9.47]	0.532	0.973 [0.61 - 1.61]	0.911	0.917 [0.48 - 1.73]	0.790
Nationality			0.074 [0.003 - 2.21]	0.083	1.96 [0.64 - 4.93]	0.186	2.286 [0.49 - 7.82]	0.225
Ethnic groups	0.985 [0.86 - 1.13]	0.826	0.723 [0.49 - 0.96]	<b>0.046 *</b>	0.95 [0.84 - 1.07]	0.426	0.967 [0.85 - 1.095]	0.6
Place of residence	0.95 [0.72 - 1.23]	0.740	0.562 [0.17 - 1.24]	0.23	0.996 [0.80 - 1.27]	0.992	0.981 [0.74 - 1.32]	0.894
Accommodation type	1.21 [0.57 - 2.40]	0.60	4.209 [0.91 - 21.62]	0.067	1.17 [0.62 - 2.37]	0.643	0.924 [0.41 - 2.23]	0.854
Family members	1.133 [0.77 - 1.66]	0.522	1.849 [0.78 - 4.78]	0.175	1.138 [0.81 - 1.6]	0.452	1.234 [0.83 - 1.85]	0.296
Maritus status	2.399 [1.08 - 4.87]	<b>0.021 *</b>	4.44 [0.28 - 54.32]	0.235	1.02 [0.47 - 2.68]	0.956	1.135 [0.43 - 3.95]	0.818
Smoking	1.004 [0.21 - 2.48]	0.995	2.897 [0.087 - 36.8]	0.457				
Alcohol	1.064 [0.18 - 3.17]	0.926	2.06 [0.066 - 30.84]	0.622	0.835 [0.32 - 3.25]	0.747		
BMI Categorized	2.015 [1.12 - 3.56]	<b>0.016 *</b>	1.215 [0.39 - 3.73]	0.729	0.785 [0.49 - 1.29]	0.329	0.718 [0.43 - 1.21]	0.206
Blood Group	1.011 [0.89 - 1.152]	0.861	1.049 [0.786 - 1.47]	0.235	1.023 [0.91 - 1.14]	0.679	0.988 [0.86 - 1.24]	0.842
Vaccination Status	1.206 [0.63 - 2.25]	0.560	0.428 [0.08 - 1.89]	0.285	4.741 [2.25 - 11.65]	<b>&lt;0.001 *</b>	2.714 [0.59 - 48.48]	0.325

OR odds ratio. Significant values are in bold.

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Table V: Multiple logistic regression of preventive measures affecting seropositivity**

Variable	<i>IgM</i>		<i>IgG</i>	
	Univariate OR (95% CI)	<i>p</i> -value	Univariate OR (95% CI)	<i>p</i> -value
Wearing masks	0.796 [0,5893 - 1,073]	0.134	0.966 [0.74 – 1.25]	0.793
Failure to respect the 2m distance	0.980 [0,7380 - 1,278]	0.886	1.229 [0.96 – 1.59]	0.108
Number of visits received in the last 14 days	0.901 [0.701 – 1.15]	0.404	1.002 [0.82 – 1.23]	0.984
Number of visits made in the last 14 days				
Wash hands with hydroalcoholic	0.854 [0.62 – 1.17]	0.327	0.891 [0.68 – 1.17]	0.405
Public transport use per day over the last 15 days	1.043 [0.75 – 1.40]	0.793	1.072 [0.82 – 1.441]	0.630
Participation in a social event in the last 15 days	0.952 [0.71 – 1.24]	0.734	1.094 [0.86 – 1.420]	0.473

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.28.24301904>; this version posted January 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).